NATIONAL COMPREHENSIVE CANCER NETWORK

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way... Learn about PYLARIFY®, a new FDA-approved imaging agent assessing patients with suspected metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated PSA.

Also known as: National Comprehensive Cancer Network, Inc, NCCN

Primary location: Billerica United States